DNA Sequencing Market Is Expected To Progress at a CAGR of 15.3% to Reach US$ 40.5 Billion by 2032 | Market.us
May 26, 2023 00:36 ET | Market.Us
New York, May 26, 2023 (GLOBE NEWSWIRE) -- According to Market.us, the DNA Sequencing Market size is projected to surpass around USD 40.5 billion by 2032 and it is poised to reach a CAGR of 15.3%...
CMC logo.png
KAIST and Checkmate Capital Complete Investment in Bredis Healthcare
May 25, 2023 18:00 ET | Checkmate Capital
Investment Accelerates Bredis’ Capacity Expansion, Integrated Platform Development and Commercialization in Korea Further Announcement of Bredis’ Agreements with Major University Hospitals SEOUL,...
NVT Logo (4).jpg
Novotech Sponsors Oncology Summit with eChina Health and Expert Panel on Drug Development Acceleration with Endpoints for ASCO 2023
May 25, 2023 17:27 ET | Novotech
CHICAGO, May 25, 2023 (GLOBE NEWSWIRE) -- Novotech, the leading Asia Pacific centred biotech CRO is sponsoring key oncology focussed expert events for ASCO: a pre-ASCO Summit with eChina Health, and...
Cybrexa Therapeutics To Present Data at ASCO 2023 Highlighting First-In-Human, Dose-Finding Study of Lead Candidate CBX-12
May 25, 2023 17:01 ET | Cybrexa Therapeutics
Activity and Safety Profile Reinforces Potential of CBX-12 in Solid TumorsFour Objective Responses Observed in Breast and Ovarian Cancers with CBX-12Dose-Limiting Toxicity Identified as...
Regeneron Logo.jpg
Fianlimab (LAG-3 inhibitor) Combined with Libtayo® (cemiplimab) Shows Clinically Meaningful and Durable Tumor Responses Across Key Advanced Melanoma Patient Populations
May 25, 2023 17:00 ET | Regeneron Pharmaceuticals, Inc.
Data demonstrate objective response rates from 56% to 63% across three independent cohorts of advanced melanoma patients – about double the rate historically seen with anti-PD-1 alone in similar...
PDS Biotech Logo.png
PDS Biotech Announces Interim Data Demonstrates 12-Month Survival Rate of 87% with PDS0101 in Combination with KEYTRUDA® (pembrolizumab) for Head and Neck Cancer Patients
May 25, 2023 17:00 ET | PDS Biotechnology Corporation
Interim data being presented at ASCO 2023 Annual Meeting Demonstrated median progression-free survival (PFS) of 10.4 months Demonstrated 12-month overall survival (OS) rate of 87.1%A disease control...
Evaxion Logo.png
Evaxion announces promising clinical Phase 1 data for its personalized cancer vaccine EVX-01
May 25, 2023 17:00 ET | Evaxion Biotech
Positive clinical response as demonstrated in 8 out of 12 patients receiving EVX-01 in combination with a checkpoint inhibitor The study met primary endpoints for tolerability and safety COPENHAGEN,...
Evaxion Logo.png
Evaxion unveils proprietary genetic adjuvant technology to boost the effect of DNA and mRNA vaccines
May 25, 2023 17:00 ET | Evaxion Biotech
Evaxion developed a genetic adjuvant technology that boosts the immune responses of viral, bacterial and cancer vaccinesPreclinically validated for both DNA and mRNA vaccines, and ready for clinical...
FCM Concerned MindMed’s Mismanagement Threatens Mental Health for Millions
May 25, 2023 16:57 ET | Concerned Shareholders of Company MindMed
MindMed has Slashed Allocation of Spending on Core Drugs While Executive Compensation has Soared to $51M MindMed Phase IIb Clinical Trial Delayed Greenleaf Health Study, Quoting FDA, Supports FCM’s...
Structure Therapeutics Initiates Phase 2a Study of Oral GLP-1 agonist GSBR-1290 for the Treatment of Type 2 Diabetes and Obesity
May 25, 2023 16:30 ET | Structure Therapeutics Inc.
12-week Phase 2a and Phase 1b multiple ascending dose (MAD) topline results expected to be announced in latter half of fourth quarter 2023 Ethnobridging study initiated in Japanese individuals and...